The European Commission approved the expanded use of Novo Nordisk A/S' diabetes medicine Fiasp to include adolescents and children aged 1 year and older.
The Denmark-based pharmaceutical giant's drug Fiasp — a fast-acting insulin — is already approved for managing diabetes in adults.
